Merck & Company Inc. (new) (MRK) Rises 2.85% for January 11

Equities Staff |

Among the biggest risers on the S&P 500 on Wednesday January 11 was Merck & Company Inc. (new) ($MRK), popping some 2.85% to a price of $61.63 a share with some 32.55 million shares trading hands.

Starting the day trading at $62.34, Merck & Company Inc. (new) reached an intraday high of $63.16 and hit intraday lows of $60.75. Shares gained $1.71 apiece by day’s end. Over the last 90 days, the stock’s average daily volume has been 10.54 million of its 2.76 billion share total float. Today’s action puts the stock’s 50-day SMA at $60.63 and 200-day SMA at $58.56 with a 52-week range of $47.97 to $65.46.

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health.

Merck & Company Inc. (new) has its corporate headquarters located in Kenilworth, NJ and employs 68,000 people. Its market cap has now risen to $169.92 billion after today’s trading, its P/E ratio is now 30.9, its P/S 5.56, P/B 3.88, and P/FCF 158.3.

You can find a complete fundamental analysis of this stock at our For a complete fundamental analysis analysis of Merck & Company Inc. (new), check out Stock Valuation Analysis tool for MRK.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investment’s Market Commentary and Adam Sarhan’s Find Leading Stocks today.

The Dow Jones Industrial Average (DJIA) is the most visible stock index in the United States, but that doesn’t make it the best. In fact, the industry standard for market watchers and institutional investors in gauging portfolio performance is the S&P 500.

The DJIA relies on just 30 stocks as a sample of large- and mega-cap firms, dwarfed by the 500 contained in the S&P 500, and it also weights its returns using an outdated and flawed price-weighting method. The S&P 500’s weighting is based on market cap, making it a much better representation of actual market performance for large- and mega-cap stocks.

To get more information on Merck & Company Inc. (new) and to follow the company’s latest updates, you can visit the company’s profile page here: MRK’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.



DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Pressure Biosciences Inc

Pressure BioSciences Inc is a biological life sciences research company. It is engaged in the development and commercialization of a platform technology called pressure cycling technology.

Private Markets

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…